STAAR Surgical Company Announces Preliminary First Quarter 2026 Financial Results

STAAR Surgical Company announced preliminary net sales for the first quarter ended April 3, 2026, exceeding $90 million, a significant increase compared to $42.6 million in the first quarter of 2025. This growth was primarily driven by strong sales in China and continued double-digit growth in the Americas. The company anticipates a meaningful improvement in adjusted EBITDA due to higher net sales and an improved cost structure. However, net sales in the Middle East and parts of EMEA and APAC regions were negatively impacted by geopolitical and macroeconomic challenges. STAAR Surgical is monitoring the situation and cautions that these conditions could continue to affect sales growth. Distributor inventory in China is now within the targeted range. The company expects to report its full financial results and file its 10-Q in early May 2026. STAAR Surgical also provided an update on its business, highlighting its position as a global leader in phakic IOLs and its EVO ICL product line.